Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous dedifferentiated fat cells (DFAT cells) are a unique population of multipotent progenitor cells derived from mature adipocytes through a process called ceiling culture. Unlike traditional adipose-derived stem cells (ASCs) which are isolated from the stromal vascular fraction, DFAT cells are produced by inducing mature, lipid-filled fat cells to undergo dedifferentiation, reverting them to a fibroblast-like multipotent state. These cells exhibit high purity and a potent capacity for angiogenesis and tissue regeneration. In the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI), DFAT cells are typically administered via intramuscular injection into the affected limb. Their therapeutic effect is primarily mediated through paracrine signaling, involving the secretion of high levels of angiogenic factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), as well as their ability to differentiate into vascular endothelial cells and smooth muscle cells to facilitate revascularization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous dedifferentiated fat cells.